SCHEMBL3204802

SCHEMBL3204802

CC1=CC(C)=C(CC(=NNC(C)(C)C)c2ccccc2)C1C

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.34
KDM4E B2RXH2 4/20 0.34
ALDH1A1 P00352 4/20 0.34
MAPT P10636 4/20 0.34
TDP1 Q9NUW8 3/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
TAAR1 Q96RJ0 1/20 0.34
CTSL P07711 1/20 0.33
SMN1; SMN2 Q16637 4/20 0.32
HPGD P15428 2/20 0.32
LMNA P02545 1/20 0.32
THRB P10828 1/20 0.32
HTT P42858 1/20 0.32
ATM Q13315 1/20 0.31
NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3199426 0.86 ALDH1A1 (0.48) GAAKDM4EALDH1A1MAPTTDP1
SCHEMBL3199307 0.81 MAPT (0.36) GAAKDM4EALDH1A1MAPTTDP1
SCHEMBL3200731 0.81 RAB9A (0.37) ALDH1A1TDP1KMT2AMEN1CTSL
SCHEMBL3216672 0.81 GAA (0.37) GAAKDM4EALDH1A1MAPTTDP1
SCHEMBL3672019 0.80 MAPT (0.36) GAAKDM4EALDH1A1MAPTTDP1
SCHEMBL3212254 0.77 KMT2A (0.39) GAAKDM4EALDH1A1MAPTTDP1
SCHEMBL3199430 0.76 ALDH1A1 (0.40) GAAKDM4EALDH1A1MAPTTDP1
SCHEMBL3207705 0.75 CTSL (0.34) GAAKDM4EALDH1A1MAPTTDP1
SCHEMBL3201625 0.73 CTSL (0.34) GAAKDM4EALDH1A1MAPTTDP1
SCHEMBL3204463 0.72 MAPT (0.45) KDM4EALDH1A1MAPTTDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732643-B2 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-08 US disclosed
US-7671226-B2 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-03-02 US disclosed
US-20100048933-A1 TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME HANAOKA HIDENORI 2010-02-25 US disclosed
US-20090054607-A1 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same HANAOKA HIDENORI 2009-02-26 US disclosed
US-7439379-B2 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL CO., LTD. (JP) 2008-10-21 US disclosed
US-20040242410-A1 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-12-02 US disclosed
EP-1426379-A1 TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME Sumitomo Chemical Company, Limited (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054607-A1 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same C1R, C1S, AP1M1 GAA 4642/4885KDM4E 4084/4885ALDH1A1 1229/4885
US-20100048933-A1 TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME C1R, C1S, AP1M1 GAA 4642/4885KDM4E 4084/4885ALDH1A1 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.